Equities
APLS – Technical Market Research
Apellis Pharmaceuticals surges 135% on Biogen’s $41/share acquisition offer. Full technical and fundamental breakdown of the deal and what it means for the tape.
Healthcare sector
Equities
Apellis Pharmaceuticals surges 135% on Biogen’s $41/share acquisition offer. Full technical and fundamental breakdown of the deal and what it means for the tape.
Equities
WVE cratered 49.6% on INLIGHT dose-response data. RSI at 19.41, volume 15x average — is this capitulation or the beginning of further downside? Rachel Kensington lays out the levels.
Equities
KOD surged 75% on GLOW2 Phase 3 success for tarcocimab (Zenkuda). RSI at 89 — deep overbought. The setup now is about defining where the mean-reversion risk is real vs. where momentum continues.
Research
Comprehensive technical analysis of CTMX covering price action, momentum, fundamental context, and the macro backdrop.
Research
Comprehensive technical analysis of AIRS covering price action, momentum, fundamental context, and the macro backdrop.
Equities
Comprehensive technical analysis of HIMS covering price action, momentum, fundamental context, and the macro backdrop.